Biologics : targets & therapy
Apatinib Plus PD-1 Blockade versus Chemotherapy After Prior Immunotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Retrospective Cohort Study
By Li RX, Yang HW, Zhang YF and 1 others.
Abstract
Objective
To compare clinical outcomes and safety of apatinib plus programmed death-1 (PD-1) blockade versus single-agent chemotherapy in patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma previously exposed to immune checkpoint inhibitors (ICIs).